Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and GIP , appears to provide a significant step forward for weight management . Early human investigations have indicated considerable losses in body mass , potentially outperforming existing obesity medications . However , further evaluation is needed to completely understa